Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. - Wikidata - wikimedia - TriplyDB

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

http://www.wikidata.org/entity/Q44486695

about

Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses Adenovirus gene transfer to amelogenesis imperfecta ameloblast-like cells Current developments in adenovirus-based cancer gene therapy Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition Circumventing antivector immunity: potential use of nonhuman adenoviral vectors SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.Calcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5.Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.Adenovirus receptors and their implications in gene delivery A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy.Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Toward gene therapy of endometriosis: transductional and transcriptional targeting of adenoviral vectors to endometriosis cells Oncolytic immunotherapy: where are we clinically?Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review)The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism.Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.Mutation in fiber of adenovirus serotype 5 gene therapy vector decreases liver tropism.A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.A dual-reporter, diagnostic vector for prostate cancer detection and tumor imaging.A genetic strategy for combined screening and localized imaging of breast cancer.Gene Therapies for Cancer: Strategies, Challenges and Successes.Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells Oncolytic virotherapy for ovarian cancer.Transductional targeting of adenovirus vectors for gene therapy Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy.Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer Gene therapy of benign gynecological diseases.A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents.Systemic delivery of a breast cancer-detecting adenovirus using targeted microbubbles A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.Strategies to enhance transductional efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application.

P2860

Q21144267-145E89E2-6BD5-4EBF-B390-A87E3273DEDB Q24293503-1069ABEA-192D-4A02-B503-8A1E7F49A4E3 Q24683229-5CFA434A-1F7A-425B-8721-8312851AC4D7 Q26739777-F71317E5-1D29-45C7-BF7E-474341FD4888 Q26995655-59E206B1-442B-4501-AF91-63986CECA223 Q27307734-F07A425B-BC59-4A33-9331-9285F6F30DC3 Q30899557-5408EB22-44F6-4D11-8B8D-1EDC007C01BA Q33659517-5113006E-74D9-46D8-B287-3D53198322CA Q33711997-0544A47A-645F-4BDE-BFCD-53F47E35BABD Q33747762-E8427F04-ED19-43CD-BFD5-9BF5D7A0AE59 Q33994011-5F4F8403-C9CD-4310-950B-898D4014FF83 Q34008026-31F668E7-EDD5-4056-A712-325D1BDD1DC7 Q34055529-E3CE36C6-81AA-41E7-90EC-D3E3334212A2 Q34102305-27CAE43E-9634-4825-9C00-42FF2EEE13F7 Q34153846-03B6D899-39A2-4A29-8326-50BA8957AD93 Q34183436-E572BDF3-02B1-4224-BE12-E5E00738B827 Q34314771-3665C367-EE42-4505-B121-26A86DFEC637 Q34405325-634E9161-F096-49E8-9C7D-DA7E63BFFFA8 Q34433546-4A1A512F-E875-46B6-943A-142C89309525 Q34462728-B3104727-BCC0-4E58-8E04-4987DD34454B Q34667746-676083BF-691E-4E72-934E-6AF42837F853 Q34830129-435BBFB6-D2D7-463B-8EE4-79AF72EE960E Q35017003-CA3330C2-10B3-47F8-AC67-58402724B95A Q35101968-887A1B0E-EF2A-4408-B744-3E5E0459DD02 Q35142325-7BA1EC15-7F08-41FC-B844-5037EEC4213C Q35151488-9C74E0E7-92CD-4F87-B714-07B643B71C00 Q35176985-95D5924D-EA18-49C8-8A69-0C6B45B09515 Q35186312-2C2D798A-EAE8-4977-B847-41EAB7F91716 Q35587169-4697A776-F2E2-4085-9FCC-1599457243AF Q35597082-72D73439-53F9-487B-A9C0-66374A62C6D2 Q35609035-2C9F4ED9-B442-4C43-A1C4-7715CC4839EF Q35620238-9579F362-4728-4043-91E0-0E8D3EE4A73F Q35665175-C8B8A4D1-F8E4-404C-8E82-8A7F07A768B6 Q35770271-61584E35-44DE-43BD-BE41-3134CD94AA1E Q35874291-12460F9D-EF97-4860-B9FB-822925D740F6 Q36158355-33B6D511-0D63-42E7-B806-5F9AB1C75D3E Q36158701-F7C03DA3-F42A-4C95-A596-4D057630CE77 Q36220624-8A8259FF-B931-417E-9816-B418E5B6F314 Q36387908-27AC1DB9-66BB-4170-AA58-9AE8947A7968 Q36387929-EB961014-F0F8-4FDA-A83C-E11C6886E5D0

P2860

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

http://www.wikidata.org/entity/Q44486695

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Targeting adenovirus to the se ...... iency to ovarian cancer cells.

@en

Targeting adenovirus to the se ...... iency to ovarian cancer cells.

@nl

type

label

Targeting adenovirus to the se ...... iency to ovarian cancer cells.

@en

Targeting adenovirus to the se ...... iency to ovarian cancer cells.

@nl

prefLabel

Targeting adenovirus to the se ...... iency to ovarian cancer cells.

@en

Targeting adenovirus to the se ...... iency to ovarian cancer cells.

@nl

P1433

Q44486695-BCB67A43-DE28-4526-9E7E-90BDBF8E0029

P1476

Q44486695-8A180FDB-9CF6-494F-8B7A-752F9FCB2C70

P2093

Q44486695-2395E42F-A62D-4557-9BE7-CA0B60F9C8BE

Q44486695-4B59F9A1-FAFB-44DD-A325-DC47DB334F5A

Q44486695-6881288A-73AF-48B2-83E1-4D8BF4F7BEF7

Q44486695-A1A2587D-4618-448F-95A2-714B84E78768

Q44486695-A4B145D8-8810-4CE6-AF97-9DEA9ED446DF

Q44486695-A57C0606-EAF7-4A75-9C86-3D000CF12C67

Q44486695-A62BC109-9037-4160-9593-FC1930548CB2

Q44486695-BB1AB3B5-1C1C-46CF-B665-12CCF835995B

Q44486695-CF1F58FB-9D2F-421B-90B3-33D4E425A6BE

Q44486695-E38038F2-F55A-48BE-8D65-3AA4EEC39973

P304

Q44486695-B39829B6-A433-4598-977E-7375F0458C9E

P31

Q44486695-31E6F407-95BD-47A4-89A4-472B62C7F577

P407

Q44486695-6646385A-33E0-48F4-A262-6FF921D94DC9

P433

Q44486695-E8B484D0-E959-456C-876F-35353C3512EB

P478

Q44486695-508A1935-0A26-469E-A5CB-1B6BAACF1840

P50

Q44486695-68BEDD24-26A0-4677-A75C-4CFB55F1B984

Q44486695-B74317E2-4FEE-41E3-93B4-66B7B63C0F6F

Q44486695-ECE71B05-1301-4826-9416-27331219B665

P577

Q44486695-CB4FC825-9676-4407-BB87-2F345D7E3FD3

P698

Q44486695-C96CC515-5810-4A67-B10B-08545A429648

P921

Q44486695-23E589AB-008E-417E-8F7B-8A31C4D54408

Q44486695-66E82F67-5828-4BAB-BF3C-022CAB9D76C5

P1433

Clinical Cancer Research

P1476

Targeting adenovirus to the se ...... ciency to ovarian cancer cells

@en

P2093

Akseli Hemminki

http://www.w3.org/2001/XMLSchema#string

Anna Kanerva

http://www.w3.org/2001/XMLSchema#string

Candace J Coolidge

http://www.w3.org/2001/XMLSchema#string

David T Curiel

http://www.w3.org/2001/XMLSchema#string

Galina V Mikheeva

http://www.w3.org/2001/XMLSchema#string

John T Lam

http://www.w3.org/2001/XMLSchema#string

Mack N Barnes

http://www.w3.org/2001/XMLSchema#string

Michael Straughn

http://www.w3.org/2001/XMLSchema#string

Parameshwar J Mahasreshti

http://www.w3.org/2001/XMLSchema#string

Ronald D Alvarez

http://www.w3.org/2001/XMLSchema#string

P304

275-280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Akseli Hemminki

David T. Curiel

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11801569

http://www.w3.org/2001/XMLSchema#string

P921